

## Report of Organizational Actions Affecting Basis of Securities

▶ See separate instructions.

**Part I Reporting Issuer**

<b>1</b> Issuer's name		<b>2</b> Issuer's employer identification number (EIN)	
Progenics Pharmaceuticals, Inc.		13-3379479	
<b>3</b> Name of contact for additional information	<b>4</b> Telephone No. of contact	<b>5</b> Email address of contact	
Eric Green	978-671-8877	eric.green@lantheus.com	
<b>6</b> Number and street (or P.O. box if mail is not delivered to street address) of contact		<b>7</b> City, town, or post office, state, and ZIP code of contact	
331 Treble Cove Rd.		N. Billerica, MA 01862	
<b>8</b> Date of action		<b>9</b> Classification and description	
June 19, 2020		Acquisition via Merger	
<b>10</b> CUSIP number	<b>11</b> Serial number(s)	<b>12</b> Ticker symbol	<b>13</b> Account number(s)
743187106		PGNX	

**Part II Organizational Action** Attach additional statements if needed. See back of form for additional questions.

**14** Describe the organizational action and, if applicable, the date of the action or the date against which shareholders' ownership is measured for the action ▶ On June 19, 2020, Lantheus Holdings, Inc. (ticker: LNTH) acquired via merger 100 percent of the outstanding shares of Progenics Pharmaceuticals, Inc. (ticker: PGNX). The transaction is expected to qualify as a tax-deferred transaction as defined under Section 368(a)(2)(E) of the Internal Revenue Code. As a result of the transaction, Progenics shares were converted to Lantheus Holdings, Inc. shares, with each share of Progenics stock converting to 0.31 shares of Lantheus stock.

**15** Describe the quantitative effect of the organizational action on the basis of the security in the hands of a U.S. taxpayer as an adjustment per share or as a percentage of old basis ▶ Each share of PGNX stock converts to 0.31 shares of Lantheus Holdings stock as of the date of the transaction. The PGNX shareholders take a carry over basis, in total, in the new Lantheus shares, and each share's basis will be adjusted by dividing the original per PGNX share basis by 0.31. The total basis in PGNX shares at the moment before the transaction will carryover to the total new Lantheus shares, while the basis per share of Lantheus shares will be increased (compared to the per share basis in PGNX shares) by dividing the original basis per share by 0.31.

**16** Describe the calculation of the change in basis and the data that supports the calculation, such as the market values of securities and the valuation dates ▶ The change in the basis arises due to the conversion ratio, which was determined at arm's length as negotiated and approved by the parties to the transaction.

**Part II** Organizational Action (continued)

**17** List the applicable Internal Revenue Code section(s) and subsection(s) upon which the tax treatment is based ▶ Sec. 368(a)(2)(E)  
Sec. 358(a)(1)

**18** Can any resulting loss be recognized? ▶ No, not with respect to this transaction.

**19** Provide any other information necessary to implement the adjustment, such as the reportable tax year ▶ The transaction occurred in 2020, thus the year 2020 would be the year to report the transaction's impacts, if any. However, the transaction was expected to qualify as a tax-deferred transaction, and as such the reporting consequences with respect to this transaction may be limited in 2020.

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.

**Sign Here** Signature ▶  Date ▶ August 3, 2020

<b>Paid Preparer Use Only</b>	Print your name ▶ <u>Brendan A. Spaeth</u>	Preparer's signature	Date ▶ <u>August 3, 2020</u>	Check <input type="checkbox"/> if self-employed	PTIN
	Firm's name ▶			Firm's EIN ▶	
	Firm's address ▶			Phone no.	